PTC Therapeutics, Inc. Annual Results: Standalone & Consolidated Reports

Annual Results

Results Snapshot

Figures in Million

Consolidate Annual Results

Dec'25

Dec'24

Dec'23

Dec'22

Dec'21

Dec'20

Dec'19

Net Sales

1,730.65

806.78

937.82

698.80

538.59

380.77

306.98

Other Operating Income

0.00

Total Operating income

1,730.65

806.78

937.82

698.80

538.59

380.77

306.98

Raw Material Cost

71.75

118.14

288.12

161.23

87.08

55.83

39.78

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

152.23

166.99

129.18

90.87

86.02

56.35

12.49

Selling and Distribution Expenses

359.34

300.91

332.54

326.00

285.77

244.46

202.54

Other Expenses

30.30

36.75

53.74

56.06

45.47

32.66

24.50

Total Expenditure (Excl Depreciation)

886.35

953.53

1,287.22

1,138.73

913.54

683.24

499.78

Operating Profit (PBDIT) excl Other Income

844.3000000000001

-146.7

-349.4

-439.90000000000003

-374.90000000000003

-302.5

-192.8

Other Income

-18.09

106.44

10.13

-31.98

-45.17

85.19

13.72

Operating Profit (PBDIT)

877.24

35.36

-102.68

-343.06

-348.59

-167.71

-143.02

Interest

152.23

166.99

129.18

90.87

86.02

56.35

12.49

Exceptional Items

10.43

-155.82

-227.66

-24.72

-12.21

-129.29

-48.36

Gross Profit (PBDT)

1,658.90

688.64

649.70

537.57

451.51

324.93

267.19

Depreciation

38.81

75.66

236.59

128.84

71.52

49.58

36.06

Profit Before Tax

696.62

-363.12

-696.11

-587.49

-518.34

-402.93

-239.93

Tax

13.97

0.18

-69.51

-28.47

5.56

35.23

11.65

Provisions and contingencies

0.00

Profit After Tax

682.64

-363.30

-626.60

-559.02

-523.90

-438.16

-251.58

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

682.64

-363.30

-626.60

-559.02

-523.90

-438.16

-251.58

Share in Profit of Associates

0.00

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

682.64

-363.30

-626.60

-559.02

-523.90

-438.16

-251.58

Equity Capital

0.00

Face Value

0.0

Reserves

-205.31

-1,098.07

-818.55

-347.09

1.44

481.98

594.33

Earnings per share (EPS)

7.78

-4.73

-8.37

-7.79

-7.43

-6.64

-4.27

Diluted Earnings per share

7.78

-4.73

-8.37

-7.79

-7.43

-6.64

-4.27

Operating Profit Margin (Excl OI)

49.49%

-18.19%

-37.26%

-62.95%

-69.62%

-79.44%

-62.8%

Gross Profit Margin

42.49%

-35.63%

-49.0%

-65.63%

-82.96%

-92.8%

-66.41%

PAT Margin

39.44%

-45.03%

-66.81%

-80.0%

-97.27%

-115.07%

-81.95%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Annual Analysis Highlights

Net Sales

YoY Growth in year ended Dec 2025 is 114.51% vs -13.97% in Dec 2024

Consolidate Net Profit

YoY Growth in year ended Dec 2025 is 287.89% vs 42.02% in Dec 2024

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Dec 2025 is 1,359.21% vs 36.97% in Dec 2024

Interest

YoY Growth in year ended Dec 2025 is -8.86% vs 29.26% in Dec 2024

Operating Profit Margin (Excl OI)

YoY Growth in year ended Dec 2025 has improved from Dec 2024

Compare Annual Results Of PTC Therapeutics, Inc. With

Select Peers

Figures in Million

Consolidate Annual Results

Change(USD)

Change(%)

Net Sales

1,730.65

0.00

1,730.65

Other Operating Income

0.00

Total Operating income

1,730.65

0.00

1,730.65

Raw Material Cost

71.75

4.14

67.61

1,633.09%

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

212.34

-212.34

-100.00%

Power Cost

0.00

Manufacturing Expenses

152.23

0.00

152.23

Selling and Distribution Expenses

359.34

106.17

253.17

238.46%

Other Expenses

30.30

42.27

-11.97

-28.32%

Total Expenditure (Excl Depreciation)

886.35

745.38

140.97

18.91%

Operating Profit (PBDIT) excl Other Income

844.31

-745.38

1,589.69

213.27%

Other Income

-18.09

7.27

-25.36

-348.83%

Operating Profit (PBDIT)

877.24

-733.97

1,611.21

219.52%

Interest

152.23

0.00

152.23

Exceptional Items

10.43

0.73

9.70

1,328.77%

Gross Profit (PBDT)

1,658.90

-4.14

1,663.04

40,170.05%

Depreciation

38.81

4.14

34.67

837.44%

Profit Before Tax

696.62

-737.38

1,434.00

194.47%

Tax

13.97

1.44

12.53

870.14%

Provisions and contingencies

0.00

Profit After Tax

682.64

-738.82

1,421.46

192.40%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

682.64

-738.82

1,421.46

192.40%

Share in Profit of Associates

0.00

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

682.64

-738.82

1,421.46

192.40%

Equity Capital

0.00

Face Value

0.00

Reserves

-205.31

52.07

-257.38

-494.30%

Earnings per share (EPS)

7.78

-6.86

14.64

213.41%

Diluted Earnings per share

7.78

-6.86

14.64

213.41%

Operating Profit Margin (Excl OI)

49.49%

0.00%

0.00

49.49%

Gross Profit Margin

42.49%

0.00%

0.00

42.49%

PAT Margin

39.44%

0.00%

0.00

39.44%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Annual - Net Sales

Net Sales 173.07 Million

in Dec 2025

Figures in Million

YoY Growth in year ended Dec 2025 is 114.51% vs -13.97% in Dec 2024

Annual - Consolidate Net Profit

Consolidate Net Profit 68.26 Million

in Dec 2025

Figures in Million

YoY Growth in year ended Dec 2025 is 287.89% vs 42.02% in Dec 2024

Annual - Operating Profit (PBDIT)

Operating Profit (PBDIT) 89.53 Million

in Dec 2025

Figures in Million

YoY Growth in year ended Dec 2025 is 1,359.21% vs 36.97% in Dec 2024

Annual - Interest

Interest 15.22 Million

in Dec 2025

Figures in Million

YoY Growth in year ended Dec 2025 is -8.86% vs 29.26% in Dec 2024

Annual - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 49.49%

in Dec 2025

Figures in %

YoY Growth in year ended Dec 2025 has improved from Dec 2024